Key result
Prophylactic treatment with enoxaparin 40 mg daily completely prevented lower extremity deep vein thrombosis (0% incidence) in 58 patients with acute ischemic stroke, without causing severe bleeding.
Why the study?
Deep vein thrombosis is a severe complication in acute ischemic stroke, but optimal enoxaparin dosing for prophylactic treatment remains elusive.
Does prophylactic enoxaparin 40 mg once daily prevent lower extremity DVT in patients with acute ischemic stroke?
Cross-Sectional (n=58)
No
Does prophylactic enoxaparin 40 mg once daily prevent lower extremity DVT in patients with acute ischemic stroke?
Prophylactic enoxaparin 40 mg daily was highly effective in preventing lower extremity DVT in acute ischemic stroke patients without significantly increasing the risk of severe bleeding or thrombocytopenia.
Background: Deep vein thrombosis (DVT) is a severe complication in patients with acute ischemic stroke. It can cause severe pulmonary embolism, which may result in death. DVT prevalence in ischemic stroke patients ranges from 20 to 70%. Enoxaparin in prophylactic treatment can decrease the risk of developing DVT in patients with acute ischemic stroke. However, optimal enoxaparin dosing for prophylactic treatment in DVT remains elusive. Dosing between 0.3 - 0.5 IU/mL could decrease the prevalence of DVT without increased complications. Objectives: This study aims to evaluate the benefits and risks of prophylactic treatment in DVT patients with dosing of enoxaparin (Lovenox of Sanofi-Aventis Vietnam Company) 40 mg (4,000 units of anti-Xa, 0.4 mL) once daily. Methods: Following a cross-sectional design, 58 patients with acute ischemic stroke, who met the inclusion criteria, were studied. Participants received prophylactic treatment of the lower extremities DVT with enoxaparin. Results: The mean Wells score was 2.14 ± 0.35. Based on the Wells criteria for DVT, all cases had paralysis, muscle weakness, and bedridden recently > 3 days. Also, 4 cases (6.9%) had leg edema; 1 case (1.7%) had superficial collateral veins; 3 cases (5.3%) had previously documented DVT. Thrombocytopenia > 50% after treatment has a non-statistically significant decrease. The 2nd ultrasound showed no case of DVT. Conclusions: Enoxaparin was not the primary cause of thrombocytopenia in prophylactic treatment. Enoxaparin is a 100% effective means to prevent lower extremity DVT in average-risk patients, and it does not increase the risk of bleeding.
No takes yet. Share an insight, caveat, or question.
Duy et al. (2022) conducted a cross-sectional in Acute Ischemic Stroke (n=58). Enoxaparin was evaluated on Incidence of deep vein thrombosis (DVT) in the lower extremities. Prophylactic treatment with enoxaparin 40 mg daily completely prevented lower extremity deep vein thrombosis (0% incidence) in 58 patients with acute ischemic stroke, without causing severe bleeding.
Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context: